Your disease area in nine scenes and thirty-six to fifty-four steps, researched and written with your team by XMap's own researchers. Every point linked to its evidence.
Annual licences to the XMap platform: the map, personas, evidence library and XMap AI, for the people you name.
Monthly check-ins and quarterly reviews, so the map moves as the evidence, the pathway and the market move.
The whole experience
of a condition,
on one surface.
- Nine scenes, from life before the condition to life after it, in three phases: before, during and after medical care.
- Every step shows the behaviours, decisions and frictions at work, and where a brand can credibly change what happens next.
- Every point opens onto its sources, with a data-quality rating. Weak evidence is shown as weak.
Illustration of the XMap platform. No client data is shown.
Life
Health
Concerns
Discovery
Diagnose
Treat
Stabilise
Progression
EndFour to six weeks.
Then it is yours.
A repeatable build, not a research project. Your team approves the steps before we build and the map before it goes live.
Define
Condition, geography, personas and evidence base agreed with your team. You approve the steps before anything is built.
Build
Our researchers populate every step: behaviours, decisions, moments, pain points, unmet needs and the evidence behind each.
Validate
Our researchers review the map, then your team does, with clinical experts and advocacy partners where you want them.
Live
The map goes live in the XMap platform for your licensed users. Monthly check-ins and quarterly reviews keep it current.
What we need from you: a cross-functional group for three or four sessions, one decision-maker to sign off, and any research of your own you want included.
Six views.
One licence.
Everything below is included in every XMap. Illustrations of the platform; no client data is shown.
The interactive map itself: nine scenes, every step, every behaviour, every unmet need, and where to act.
The executive read: where experience is costing outcomes, on one page.
Patient, caregiver and clinician personas built from behaviour, not demographics.
Where different populations take different paths through the same condition.
Every source behind the map, labelled public or yours, quality-rated and open to inspect.
Ask the map a question in plain language. Answers come only from your map's approved evidence.
Not another journey map.
A journey map describes the part of the market you can already see. XMap shows the part you cannot, and holds up when you act on it.
Starts at diagnosis. Ends at prescription.
Starts before anyone knows they are at risk. Ends when the person leaves the healthcare system.
Maps touchpoints and channels.
Maps behaviour: the beliefs, decisions and frictions that decide what happens next.
Follows the patient alone.
Follows the patient and the clinician: two histories that meet in one consultation, where most of the decision is already made.
A deck you take on trust.
A living map. Every point linked to its evidence and open to challenge.
The patient arrives with a history. So does the clinician. By the time a brand acts, most of the decision has been made. XMap shows how, and where it could have been shaped.
Four teams.
One map.
One evidence base that brand, medical, market access and insights all work from, each for their own reasons.
Where behaviour shapes outcomes before the brand decision is visible, and so where to focus and invest.
Where clinical evidence and lived experience part company: the gaps better scientific exchange would close.
Where policy, pathway, funding and capacity create friction, and what must change for patients to reach care.
Fragmented research in one connected view, with the gaps and contradictions that should direct the next study.
Keep what you do well. Add what no single brief can afford.
Your client relationship, judgement and creative work are the value. XMap gives that work an evidence base across the whole condition, and a standard way to build it.
The XMap team builds the map with your client's team in four to six weeks. You build your strategy on it.
Our training, templates and platform give your team a standard way to collect what an XMap needs. Same technology, your hands.
Nearly thirty
disease areas.
From rare disease and hospital procedures to the largest populations, for global pharmaceutical companies. We name the companies in a conversation, not on a website. The conditions we can.
- Acute coronary syndrome
- Acute respiratory failure
- Asthma
- Bronchoscopy
- Cardiac catheterisation
- Chronic kidney disease
- Colonoscopy
- Complicated intra-abdominal infection
- COPD
- COVID-19
- Dyslipidemia
- Eosinophilic oesophagitis
- Heart failure
- Hypertension
- Influenza
- Life-threatening bleeds
- NASH
- Neurofibromatosis type 1
- Opioid-induced constipation
- Osteoarthritic pain
- Ovarian cancer
- Post-myocardial infarction
- Procedural sedation
- Prostate cancer
- Septic shock
- Stroke
- Systemic lupus erythematosus
- Transthyretin amyloidosis
- Type 2 diabetes
Priced per map.
Licensed per year.
A proposal has two parts: the build of your map, and the annual licence for the platform and the people who work in it. Tell us the condition and market and we come back with a scope and a quote.
Ask for an indicative scope →How many populations experience the condition differently, and the treatment lines involved.
How many personas the map is built around, and how many steps are developed in full.
The depth of evidence behind each point, and whether your own research is brought in.
How many people hold a licence to explore, question and work in the map.
Nothing is taken
on trust.
Published literature, clinical guidelines, registry and real-world data, health system and pathway documentation, and any approved research you already own. Every source is labelled.
Yes. Your research is used only in your map. You decide who can open the map and the evidence behind it. Each client runs in an isolated tenant on Microsoft Azure, encrypted in transit and at rest.
AI structures and connects evidence at a scale people cannot. It is held to the approved source base for your map and does not generate evidence of its own. People decide what is true and what matters.
Every step, behaviour and unmet need is reviewed by our researchers, then approved by your team, with clinical experts and advocacy partners in validation where you want them.
Monthly check-ins and quarterly reviews are part of the licence. New evidence, pathway changes and your own new research are worked into the map, so it stays the version everyone trusts.
See a
live map.
Thirty minutes, a live map, one of us. We open it together, look at the evidence and XMap AI, and you decide what is worth keeping.
hello@uservox.com
UK +44 (0)1935 676980
Thank you.
We will be in touch shortly to arrange your walkthrough.